AUDIO JOURNAL OF ONCOLOGY—First Line Atezolizumab Extends Life in Unfit Patients with Lung Cancer

PARIS, France—the open-label international phase three randomized IPSOS study reported at the 2022 European Society for Medical Oncology congress that patients with non-small cell lung cancer who were not fit enough to be recommended standard platinum doublet chemotherapy lived longer when treated with the programmed death-ligand 1 (PD-L1) inhibitor atezolizumab than patients in a comparison group who received a single-agent chemotherapy regimen.

https://cslide.ctimeetingtech.com/esmo2022/attendee/confcal/session/calendar/2022-09-12

Faced with the reality that a large unfit population of patients with non-small cell lung cancer cannot be recommended standard treatment (and who typically received single agent chemotherapy, or best supportive car) Siow Ming Lee, PhD FRCP, IPSOS Trial Chair, Professor of Medical Oncology and Consultant Medical Oncologist at University College London Hospital, told the Audio Journal of Oncology’s Peter Goodwin how they investigated the use of single-agent atezolizumab checkpoint inhibition immunotherapy in patients deliberately chosen for their low performance status who had no proven options for initial treatment.